Mandate

Vinge advises Region Uppsala in connection with health impact bonds

December 14, 2023 Banking and Finance

Vinge has advised Region Uppsala in connection with its issuance of a so-called health impact bond in the amount of SEK 80 million and with a tenor of five years. The health impact bond is the second of its kind in the world and comes after Region Stockholm’s bond which was linked to preventive measures against type 2 diabetes. Skandia was the sole investor and SEB acted as financial advisor and issuing agent.

The health impact bond is a bespoke product that finances preventive interventions to detect and offer potentially life-saving treatment to people with undiagnosed high blood pressure and other related risk factors. The preventive interventions are expected to prevent up to 650 materially adverse cardiovascular events and generate cost savings of approximately SEK 160 million over ten years.

A distinct and unique feature of the health impact bond is its yield model, which is outcome-based and involves risk sharing between the issuer and the investor. If the issuer’s initiatives achieve the expected results, the investor will receive a higher return on its investment, but if the issuer does not achieve the expected results, the return will be lower or even negative (i.e., the investor will get back less than their invested amount).

For more information (Swedish only), please refer to https://regionuppsala.se/politik-och-paverkan/pressrum/2023/december/satsar-stort-mot-hogt-blodtryck-genom-att-ge-ut-halsoobligation/.

The Vinge team consisted of Albert Wållgren, Lionardo Ojeda and Sofia Haggren.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024